References
- Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J
Psychiatry. 2007;164(6):870.
- Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant
syndrome–a case review. Hum Psychopharmacol. 2003;18(4):301.
- Desai D, Gupta K, Kumar R, Biswas A. Levosulpiride-induced neuroleptic
malignant syndrome in rheumatoid arthritis. BMJ Case Rep. 2018;2018
Epub 2018 Aug 11.
- Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention
and management. Drug Saf. 1998;19(1):73.
- Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE.
Progression of symptoms in neuroleptic malignant syndrome. J NervMent
Dis. 1994;182(3):168.
- Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry.
1985;142(10):1137.
- Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE Jr.
Atypical neuroleptic malignant syndrome: diagnostic controversies and
considerations. Pharmacotherapy. 2008;28(4):530.
- Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am.
1993;77(1):185.
- Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant
syndrome. J Clin Psychiatry. 1989;50(1):18.
- Young Kyoung Sa et al. Olanzapine-Induced Diabetic Ketoacidosis and
Neuroleptic Malignant Syndrome with Rhabdomyolysis: A Case Report.
Endocrinol Metab 2013; 28:70-75.
- Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome. Ann Pharmacother.
2016;50(11):973. Epub 2016 Jul 19.
- Ann Pharmacother. 2016;50(11):973. Epub 2016 Jul 19. Recurrent sinus
arrest in association with neuroleptic malignant syndrome. Br J
Psychiatry. 1994;164(5):689.
- GuzéBH, Baxter LR Jr. Current concepts. Neuroleptic malignant
syndrome. N Engl J Med. 1985;313(3):163.
- Lappa A, PodestàM, Capelli O, Castagna A, Di Placido G, Alampi D,
Semeraro F. Successful treatment of a complicated case of neuroleptic
malignant syndrome. Intensive Care Med. 2002;28(7):976. Epub 2002 Jun
7.
- Morgan C,Rowe R. The prevalence of neuroleptic malignant syndrome in
learning disability. Irish Journal of Psychological Medicine 2003.
- SheehanR,HorsfallL,StrydomA,OsbornD,Walters K,Hassiotis A. Movement
side effects of antipsychoticdrugs in adults with and
withoutintellectual disability: UK populationbasedcohort study. BMJ
Open 2017;7:e017406.
- Kaufman K, Levitt MJ, Shiltz JF, Sunderram J. Neuroleptic Malignant
Syndrome and Serotonin Syndrome in the Critical Care Setting: Case
Analysis. Annals of Clinical Psychiatry, 18[3]:201–204, 2006
- HernándezJL,RamosF,InfanteJ,Rebollo M, González-Macías J. Severe
Serotonin Syndrome Induced by Mirtazapine Monotherapy. The Annals of
Pharmacotherapy. 2002 April, Volume 36
- SchattnerA,KitroserE,Cohen JD.Fatal Neuroleptic Malignant Syndrome
Associated With Quetiapine.American Journal of Therapeutics 0, 1–2
(2015).
- O’Dwyer
AM and Sheppard
N. The role of creatine kinase in the diagnosis of Neuroleptic
Malignant Syndrome. Psychological Medicine, 1993, 23, 323-326.
- BNF – British National Formulary 79 March - September 2020.